{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:08:36Z","timestamp":1784610516513,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["oooojournal.net","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.oooo.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T03:57:22Z","timestamp":1520308642000},"page":"547-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw"],"prefix":"10.1016","volume":"125","author":[{"given":"Tomoko","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kajizono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2018.02.010_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.oooo.2018.02.010_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.02.010_bib0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.oooo.2018.02.010_bib0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.02.010_bib0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.oooo.2018.02.010_bib0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2018.02.010_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Suppor Care Cancer"},{"key":"10.1016\/j.oooo.2018.02.010_bib0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.oooo.2018.02.010_bib0050","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.2174\/0929867324666170511113811","article-title":"Osteonecrosis of the jaw and angiogenesis inhibitors: a revival of a rare but serous side effect","volume":"24","author":"Antonuzzo","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.oooo.2018.02.010_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.02.010_bib0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.oooo.2018.02.010_bib0065","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.02.010_bib0070","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2018.02.010_bib0075","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.oooo.2018.02.010_bib0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coms.2015.06.002","article-title":"Medication-related osteonecrosis of the jaw: basic and translational science updates","volume":"27","author":"Allen","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.oooo.2018.02.010_bib0085","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","article-title":"Denosumab dose selection for patients with bone metastases from solid tumors","volume":"18","author":"Doshi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2018.02.010_bib0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.oooo.2018.02.010_bib0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-011-1429-y","article-title":"Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II\/III breast cancer","volume":"127","author":"Coleman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.oooo.2018.02.010_bib0100","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.02.010_bib0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.oooo.2018.02.010_bib0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis","volume":"116","author":"Mauri","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.oooo.2018.02.010_bib0115","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318300816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440318300816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T02:25:42Z","timestamp":1658197542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440318300816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2212440318300816"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2018.02.010","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}